Psychiatrist

Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder

Retrieved on: 
Tuesday, December 19, 2023
Trauma, The Institute, Psilocybin, Lead, Psychiatrist, Mental health, PTSD, Sunstone, Post-traumatic stress disorder, Psychology, Safety, Patient, CMPS, Pharmaceutical industry

This is believed to be the first study reporting on the feasibility of psilocybin as a potential treatment for PTSD.

Key Points: 
  • This is believed to be the first study reporting on the feasibility of psilocybin as a potential treatment for PTSD.
  • The open-label study evaluated the safety and tolerability of COMP360 psilocybin treatment in patients with PTSD as a result of trauma experienced as adults.
  • 22 participants received a single 25mg dose of investigational COMP360 psilocybin treatment.
  • It’s encouraging to see these initial safety results for COMP360 psilocybin treatment in this patient population and we look forward to a more detailed analysis of the study next year.”

Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression and launches new research center

Retrieved on: 
Wednesday, November 15, 2023
Psilocybin, COMP, Depression, Safety, CMPS, Psychology, Maudsley Hospital, Mental health, Maudsley, Psychiatrist, NIHR, Trial of the century, TRD, Partnership, Anorexia nervosa, Suicide, Lead, Nursing, Pharmaceutical industry, Compass, Research, Innovation

The ongoing phase 3 program is the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted and follows promising results from Compass’s phase 2b study of COMP360 psilocybin treatment.

Key Points: 
  • The ongoing phase 3 program is the largest randomized, controlled, double-blind psilocybin treatment clinical program ever conducted and follows promising results from Compass’s phase 2b study of COMP360 psilocybin treatment.
  • The phase 3 program consists of two pivotal trials (COMP 005 and COMP 006), and each trial has an integrated, long-term outcomes component.
  • COMP 006 will take place in the UK and globally and will study three dose arms of COMP360 (25mg, 10mg and 1mg).
  • COMP 005 is a US-based trial examining the effect of a single 25mg dose of COMP360 psilocybin, compared with placebo.

AliveCor's KardiaMobile® 6L Becomes First Personal ECG Device Recommended for Use in Psychiatric Services in England and Wales

Retrieved on: 
Tuesday, September 26, 2023
Criticism of the National Health Service (England), Travel, Diuretic, National Health Service, Intersex, Anxiety, Electricity, Business, ECG, QT, Tees, Esk and Wear Valleys NHS Foundation Trust, EVA, Psychiatrist, QT interval, Patient, Collection, Physician, National Institute for Health and Care Excellence, NHS, Cardiology, NICE, Hospital, Pharmaceutical industry, Medical imaging, Birth control, Alivecor

1, 2 KardiaMobile 6L is a portable ECG recording device that provides instant detection of cardiac abnormalities and can be used to measure heart changes including cardiac QT interval.1

Key Points: 
  • 1, 2 KardiaMobile 6L is a portable ECG recording device that provides instant detection of cardiac abnormalities and can be used to measure heart changes including cardiac QT interval.1
    "Timely ECG monitoring of patients who are on antipsychotic medication can save lives.
  • Having access to KardiaMobile 6L will mean potentially vulnerable patients can now be seen in the comfort of their homes, reducing their stress whilst ensuring that this essential monitoring is completed anywhere, at any time.
  • KardiaMobile 6L has been recommended as part of NICE's EVA pilot project, created to drive earlier access to promising healthcare innovations for use within the National Health Service in England and Wales.
  • "We have a wealth of clinical data on the use of KardiaMobile 6L in cardiology, with NICE's EVA recommendation we will now support the collection of real-world evidence as to its effectiveness in psychiatric services.

Beckley Psytech Launches Phase IIa Study of Lead Candidate BPL-003, a Novel Benzoate Formulation of 5-MeO-DMT, for Treatment Resistant Depression

Retrieved on: 
Wednesday, December 21, 2022
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, TRD, Beckley Foundation, MDD, 5-Methoxy-N,N-diisopropyltryptamine, Research, Depression (mood), Psychiatrist, Depression, University College London Hospitals NHS Foundation Trust, Patient, Treatment, Psilocybin, Safety, HMR, King's College London, King, Principal, Pharmaceutical industry

Beckley Psytech Ltd, a private, clinical-stage biotechnology company dedicated to addressing neuropsychiatric conditions through the novel application of psychedelic medicines, today announced that it had initiated a Phase IIa study investigating BPL-003, a proprietary intranasal formulation of synthetic 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), for Treatment Resistant Depression (TRD).

Key Points: 
  • Beckley Psytech Ltd, a private, clinical-stage biotechnology company dedicated to addressing neuropsychiatric conditions through the novel application of psychedelic medicines, today announced that it had initiated a Phase IIa study investigating BPL-003, a proprietary intranasal formulation of synthetic 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), for Treatment Resistant Depression (TRD).
  • Depression affects around 280 million people around the world , but 30% of those living with the condition are resistant to available antidepressant medications , meaning there is an urgent need for more effective treatments.
  • Patients will be followed for 12 weeks after initial dosing, with safety, pharmacokinetic and efficacy assessments conducted at multiple points throughout that period.
  • Cosmo Feilding Mellen, CEO of Beckley Psytech, said: “Conditions like Treatment Resistant Depression have a devastating effect on people around the world, but they are sadly underserved when it comes to treatment opportunities.

Eileen A. Zhivago, MD is recognized by Continental Who's Who

Retrieved on: 
Friday, September 9, 2022
American, Wellness, Adolescence, American Medical Association, Mount, St. Luke's International Hospital, MD, Psychiatrist, Continental, Multimedia, Clinical, Indian Medical Association, Education, The Journal of Neuropsychiatry and Clinical Neurosciences, New Jersey Medical School, Psychiatric Services, Child and adolescent psychiatry, American Journal, Founder, Neuropsychiatry, Journal, American Academy, Weather, American Academy of Child and Adolescent Psychiatry, Believer, Walking, American Psychiatric Association, American Board of Commissioners for Foreign Missions, ABPN, American Board of Psychiatry and Neurology, Institute, Medicine, Patient, Pharmacy, Child, Neurology, Psychiatry

WESTFIELD, N.J., Sept. 9, 2022 /PRNewswire/ -- Eileen A. Zhivago, MD, is being recognized by Continental Who's Who as a Trusted Psychiatrist and in acknowledgment of her outstanding work at Cohesive Health and Wellness.

Key Points: 
  • WESTFIELD, N.J., Sept. 9, 2022 /PRNewswire/ -- Eileen A. Zhivago, MD, is being recognized by Continental Who's Who as a Trusted Psychiatrist and in acknowledgment of her outstanding work at Cohesive Health and Wellness.
  • As a double board-certified Psychiatrist, Dr. Zhivago works with kids and their families to understand and treat family issues and mental health issues.
  • Inspired by her grandfather, who was a Physician in Europe, Dr. Zhivago wanted to help people, too.
  • Awarded for her success, Dr. Zhivago was named among New Jersey's Favorite Kids' Docs in 2020.

Arkansas Medical, Dental, and Pharmaceutical Association, Inc. (AMDPA) Announces New President in First In-Person Scientific Session in Three Years

Retrieved on: 
Saturday, June 11, 2022
Eye, Association, Goal, Dentist, Research, Mental health, Firearm, Associate, Gunpoint, Health equity, Policy, Pharmacist, Arkansas Medical Cannabis Act, Psychiatrist, Psychiatry, Workforce, University, Physician, Therapy, Health, Chinese Pharmaceutical Association, Violence, COVID-19, MD, ROCK, Department, Medicine, Practice, Medical device, Black

LITTLE ROCK, Ariz., June 11, 2022 /PRNewswire/ -- The Arkansas Medical, Dental, and Pharmaceutical Association, Inc  (AMDPA) announces Dr. Rhonda Mattox, who was previously President-Elect, as the new President on June 11, 2022.

Key Points: 
  • LITTLE ROCK, Ariz., June 11, 2022 /PRNewswire/ -- The Arkansas Medical, Dental, and Pharmaceutical Association, Inc (AMDPA) announces Dr. Rhonda Mattox, who was previously President-Elect, as the new President on June 11, 2022.
  • She serves as an integrative behavioral health psychiatrist and mental health consultant to primary care providers across the state of Arkansas.
  • It is the only interprofessional organization of health care providers including physicians, dentists, pharmacists, physical therapists and physician assistants in Arkansas.
  • Here's a video of Dr. Rhonda Mattox from 2017 at the AMDPA Scientific Session

Eileen A. Zhivago, MD, is recognized by Continental Who's Who

Retrieved on: 
Friday, April 22, 2022
American Board of Psychiatry and Neurology, Wellness, American Board of Commissioners for Foreign Missions, Believer, Indian Medical Association, Adolescence, American Academy of Child and Adolescent Psychiatry, Weather, MD, Medicine, American Journal, Child and adolescent psychiatry, Continental, The Journal of Neuropsychiatry and Clinical Neurosciences, Education, Patient, Clinical, Walking, Founder, Neuropsychiatry, New Jersey Medical School, Mount, Psychiatric Services, Psychiatrist, Journal, American Academy, American, American Psychiatric Association, St. Luke's International Hospital, Institute, ABPN, American Medical Association, Child, Neurology, Psychiatry, Pharmacy

WESTFIELD, N.J., April 22, 2022 /PRNewswire/ -- Eileen A. Zhivago, MD, is being recognized by Continental Who's Who as a Top Pinnacle Psychiatrist and in acknowledgment of her work at Cohesive Health and Wellness.

Key Points: 
  • WESTFIELD, N.J., April 22, 2022 /PRNewswire/ -- Eileen A. Zhivago, MD, is being recognized by Continental Who's Who as a Top Pinnacle Psychiatrist and in acknowledgment of her work at Cohesive Health and Wellness.
  • As a double board-certified Psychiatrist, Dr. Zhivago works with kids and their families to understand and treat family issues and mental health issues.
  • Inspired by her grandfather, who was a Physician in Europe, Dr. Zhivago wanted to help people, too.
  • Dr. Zhivago has also given presentations at the American Psychiatric Association, the American Medical Association, and the Institute of Psychiatric Services.

Longboard Pharmaceuticals Appoints Life Sciences Executive Dr. Jane Tiller to Board of Directors

Retrieved on: 
Wednesday, November 17, 2021
Private Securities Litigation Reform Act, Judgement, Security (finance), GPCR, Anxiety, G protein-coupled receptor, Neuroscience, Industry, BMS, Sleep, Bristol Myers Squibb, Seizure, SEC, Central nervous system, Neuroinflammation, SAN, Maudsley Hospital, Senior lecturer, U.S. Securities and Exchange Commission, University, Neurodegeneration, Medicine, Virology, Psychiatrist, Clinical research, Research, Schizophrenia, GLOBE, University of Glasgow Medical School, Board, Prunus, Therapy, Global Medical Device Nomenclature, Bipolar disorder, Lists of diseases, Cephalon, Drexel University, CB2, Pharmaceutical industry

SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the appointment of Jane Tiller, MBChB, FRCPsych, to its board of directors.

Key Points: 
  • SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the appointment of Jane Tiller, MBChB, FRCPsych, to its board of directors.
  • "We are thrilled to further strengthen the deep expertise of our Board with the addition of Dr. Tiller.
  • "These attributes will be invaluable as we advance and expand our robust pipeline and continue to build a world-class team."
  • Longboard disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Mycotopia Therapies Appoints Experienced Mental Health Professional Senator Dr. Saphire Longmore M.B.B.S., DM As Chief Medical Officer Of Caribbean Affairs

Retrieved on: 
Wednesday, November 10, 2021
Universe, Bipolar disorder, Form, Suicidal ideation, Private Securities Litigation Reform Act, Anxiety, American Psychiatric Association, Medicine, Senate, Medical Council of Jamaica, Depression, Security (finance), CEO, Hand, Teaching hospital, Psychotherapy, COVID-19, Risk, Medical Council, General Medical Council, Growth, USA, Jamaica Social Investment Fund, American, Schizophrenia, Forward-looking statement, NJCAA National Football Championship, Psychiatrist, Board, Incidence, Company, U.S. Securities and Exchange Commission, Mental health, GLOBE, TPIA, SEC, OTC Markets Group, Private practice, Medical Association of Jamaica, DM, Parliament, United Kingdom, Pharmaceutical industry

MIAMI, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc. (OTC Pink: TPIA) (the Company) today announced the appointment of Saphire Longmore M.B.B.S., DM, to the role of Chief Medical Officer of Caribbean Affairs.

Key Points: 
  • MIAMI, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc. (OTC Pink: TPIA) (the Company) today announced the appointment of Saphire Longmore M.B.B.S., DM, to the role of Chief Medical Officer of Caribbean Affairs.
  • She is also a member of the American Psychiatric Association, the Medical Council of Jamaica, the General Medical Council of the United Kingdom, the Medical Association of Jamaica.
  • Senator Dr. Longmore said, I am enthusiastic to be joining Mycotopia Therapies at such a pivotal stage in its growth.
  • We are fortunate at Mycotopia Therapies to be able to tap into the experience of an individual like Senator Dr. Saphire Longmore, stated Ben Kaplan, CEO of Mycotopia Therapies.

Clinical Director of Imperial College's Center for Psychedelic Research Joins Entheon Advisory Board

Retrieved on: 
Wednesday, August 25, 2021
Union, Company, FSE, Columbia University, Neuropsychopharmacology, CSE, Center, Neuroscience, Psychiatrist, National Health Service, St Charles' Hospital, Physician, European Union, Psychedelic drug, Research, PET, Doctor of Philosophy, Imperial College London, DMT, Biotechnology, Board, ST, NHS, Psychiatry, Depression, Advisory board, MRI, Sale, Imperial College Healthcare NHS Trust, BHS, Substance use disorder, Therapy, Pharmaceutical industry, Medicine

Dr. David Erritzoe to provide guidance on psychopharmacological research

Key Points: 
  • Vancouver, British Columbia--(Newsfile Corp. - August 25, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that Dr. David Erritzoe, the current Clinical Director of the Imperial College's Center for Psychedelic Research, has been appointed to Entheon's Advisory Board.
  • Dr. Erritzoe has significant experience in psychiatry, neuropsychopharmacology and psychedelic research.
  • He is currently leading a new National Health Service (BHS) based research clinic, the CIPPRes Clinic, a collaborative, multidisciplinary research initiative between the Imperial College in London and the St. Charles Hospital.
  • Dr. Erritzoe conducts research using brain imaging techniques including PET and MRI scans and has conducted research into the neurobiology of addictions and depression.